Role of chymase on vascular proliferation

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 1, 2000, Pages 23-26

  Miyazaki, Mizuo ^a   Takai, Shinji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Chymase; Inhibitor; Proliferation

Indexed keywords

ANGIOTENSIN II; CHYMASE; SERINE PROTEINASE;

ANGIOGENESIS; ANIMAL; BIOSYNTHESIS; BLOOD VESSEL; EDITORIAL; HUMAN; INJURY; METABOLISM; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; BLOOD VESSELS; CHYMASES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SERINE ENDOPEPTIDASES; WOUNDS AND INJURIES;

EID: 0034160523     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.004     Document Type: Review

References (48)

1. Hackenthal E, Hackenthal R, Hilgenfeldt U. Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensin-forming enzymes. Biochim Biophys Acta 1978; 522: 574-88.
2. Reilly CF, Tewksbury DA, Schechter NM, Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cellproteinases. J Biol Chem 1982; 257: 8619-22.
3. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997; 412: 86-90.
4. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996; 58: 591-97.
5. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 1982; 257; 15042-46.
6. Wintroub BU, Klickstein LB, Dzau VJ, Watt KW. Granulocyte-angiotensin system. Identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochemistry 1984; 23: 227-32.
7. Boucher R, Demassieux S, Garcia R, Genest J. Tonin, angiotensin II system. A review. Circ Res 1977; 41 (4 Suppl. 2): 26-9.
8. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system'. Nature 1980; 288: 705-6.
9. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2: 277-84.
10. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987; 149: 1186-92.
11. Schwartz LB, Austen KF. Structure and function of the chemical mediators of mast cells. Prog Allergy 1984; 34: 271-321.
12. Yurt RW, Austen KF. Preparative purification of the rat mast cell chymase: characterization and Interaction with granule components. J Exp Med 1977; 146:1405-19.
13. Pejler G, Berg L. Regulation of rat mast cell protease I activity: protease inhibition is prevented by heparin proteoglycan. Eur J Biochem 1995; 233: 192-9.
14. Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dcpendent angiotensin II formation in human vascular tissue. Circulation 1999; 100: 654-658.
15. Le Trong H, Parmelee DC, Walsh KA, Neurath H, Woodbury RG. Amino acid sequence of rat mast cell protease I (chymase). Biochemistry 1987; 26: 6988-94.
16. Le Trong H, Neurath H, Wbodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cell. Proc Natl Acad Sci USA 1987; 84: 364-7.
17. Benfey PN, Yin FH, Leder P. Cloning of the mast cell protease, RMCP II. Evidence for cell-specific expression and multi-gene family. J Biol Chem 1987; 262: 5377-84.
18. Caughey GH, Viro NF, Ramachandran J, Lazarus SC, Borson DB, Nadel JA. Dog mastocytoma tryptase: affinity purification, characterization, and amino-terminal sequence. Arch Biochem Biophys 1987; 258: 555-63.
19. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactlve intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988; 244: 133-7.
20. Wintroub BU, Schechter NM, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic protainases. J Invest Dermatol 1984; 83: 336-9.
21. Urata H, Kinoshita A, Misono K, Bumpus M, Husain A. Identification of highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-57.
22. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin Chim Acta 1997; 265: 13-20.
23. Takai S, Shiota N, Jin D, Miyazaki M. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol 1998; 32: 826-33.
24. Goldstein SM, Kaempfer CE, Proud D, Schwartz LB, Irani A-MA, Wintroub BU. Detection and partial characterization of a human mast cell carboxypeptidase. J Immunol 1987; 139: 2724-29.
25. Goldstein SM, Kaempfer CE, Kealey JT, Wintroub BU. Human mast cell carboxypeptidase. J Clin Invest 1989; 83: 1630-6.
26. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 1993; 62: 207-10.
27. Okunishi H, Kawamoto T, Kurobe Y et al. Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1991; 18: 649-59.
28. Miyazaki M, Okamura T, Toda N. Role of vascular angiotensin-converting system in hypertension. J Hypertens 1988; 6 (Suppl 3): S13-S15.
29. Miyazaki M, Okamura T, Okunishi H, Toda N. Vascular angiotensin-converting enzyme in the development of renal hypertension. J Cardiovasc Pharmacol 1986; 8 (Suppl 10): S58-S61.
30. Miyazaki M, Okunishi H, Okamura T, Toda N. Elevated vascular angiotensin-converting enzyme in chronic two-kidney, one clip hypertension in the dog. J Hypertens 1987; 5: 155-60.
31. Jin D, Takai S, Shiota N, Miyazaki M. Roles of vascular angiotensin-converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J Hypertens 1998; 16: 657-664.
32. Naftilan AJ, Gilliland G, Eldridge CS, Kraft AS. Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990; 10:5536-10.
33. Schelling H, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991; 9: 3-15.
34. Powell JS, Muller RKM, Rouge M, Kuhn H, Hefti F, Baumgartner HR.The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1990; 16: S42-S49.
35. Powell JS, Clozel JP, Muler RKM et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1991; 245: 186-8.
36. MARCATOR Study Group. Does the new angiotensin-converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MARCATOR Study. Circulation 1992; 86: 100-10.
37. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicentcr American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 2: 362-9.
38. Miyazaki M, Wada T, Shiota N, Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 1999; 13 Suppl 1:S21-S25.
39. Miyazaki M, Shiota N, Sakonjo H, Takai S. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog. Jpn J Pharmacol 1999; 79: 455-460.
40. Tamai H, Katoh O, Suzuki S et al. Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis following Angioplasty Trial (TREAT). Am Heart J 1999; 138: 968-75.
41. Azuma H, Banno K, Yoshimura T. Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol 1976; 58: 483-8.
42. Isaji M, Nakajoh M, Naito J. Selective inhibition of collagen accumulation by N-(3,4-dimethoxycinnamoyl) anthranilic acid (N-5′) in granulation tissue. Biochem Pharmacol 1987; 36: 469-74.
43. Jin D, Takai S, Shiota N, Miyazaki M. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur J Pharmacol 1998; 361: 199-205.
44. Hanson R, Powell JS, Dodson T et al. Effects of angiotensin-converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 1991; 18 (4 Suppl): 1170-76.
45. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science 1996; 271: 502-5.
46. Takai S, Yuda A, Jin D et al. Inhibition of Chymase Reduces Vascular Proliferation in Dog Grafted Veins. FEBS Lett. (in press).
47. McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochem Biophys Acta 1995; 1267: 115-21.
48. Craig SS, Schwartz LB. Human MCTC type of mast cell granule: the uncommon occurrence of discrete serous associated with focal absence of chymase. Lab Invest 1990; 63: 581-5.